Complete BMI Guide & Immediate Wegovy Availability UK
BMI Requirements For Wegovy - Currently Available In Stock UK
The BMI criteria for Wegovy in the UK are clearly defined by MHRA licensing and NICE guidance TA875. Adults require a BMI of 30 kg/m² or above, or a BMI of 27 kg/m² or above with at least one weight-related health condition such as type 2 diabetes, high blood pressure, or sleep apnoea. What makes EverydayMeds unique is our Stock Available availability - whilst other providers have faced intermittent shortages, our direct supply chain with Novo Nordisk ensures all five Wegovy doses remain consistently available.
Understanding your BMI for Wegovy eligibility is the first step, but securing reliable supply is equally crucial for successful treatment. Our clinical team at GPhC-registered pharmacy #9012878 can verify your BMI qualification during the assessment process, whilst simultaneously guaranteeing that your prescribed dose is ready for immediate dispatch. This eliminates the frustration of meeting eligibility criteria only to face months-long waiting lists experienced elsewhere.
Wegovy Pricing Structure - All BMI-Eligible Doses In Stock
For patients who meet the BMI requirements for Wegovy, our complete pricing structure covers the entire dose escalation pathway. Starting doses begin at £79.99 for the 0.25mg pen (weeks 1-4), progressing through £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and reaching the maintenance 2.4mg dose at £209.99. New customers benefit from discount code FIRST40 applied at checkout, whilst returning patients use code DOSE25 to reach these competitive prices.
Our bundle options provide convenience for BMI-qualified patients planning their treatment journey. The Intro Duo combining 0.25mg and 0.5mg costs £169.99, covering your first 8 weeks of treatment, whilst the Progress Trio (0.5mg, 1mg, and 1.7mg) at £369.99 ensures 12 weeks of uninterrupted dose escalation. These bundles eliminate the need for multiple orders and assurance continued supply throughout your initial treatment phase, addressing the availability concerns that have affected other UK suppliers.
Clinical Evidence Supporting BMI For Wegovy Treatment
The STEP clinical trial programme established the BMI thresholds for Wegovy based on robust efficacy data. In the landmark STEP 1 trial (Wilding et al., NEJM, 2021), patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. These results specifically included participants meeting the current BMI criteria for Wegovy prescription.
Long-term sustainability data from STEP 5 demonstrated that patients meeting the BMI requirements for Wegovy maintained approximately clinically studied weight loss at two years when continuing treatment. The SELECT cardiovascular outcomes trial further validated the BMI thresholds by showing a 20% reduction in major cardiovascular events (HR 0.80) among participants who met the established BMI criteria for Wegovy eligibility.
How Wegovy Works For BMI-Eligible Patients
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone responsible for regulating appetite and food intake. For patients meeting the BMI requirements, this prescription-only medicine works by binding to GLP-1 receptors in the brain, reducing appetite signals and promoting feelings of fullness after smaller meals. The medication may also slow gastric emptying, helping you feel satisfied for longer periods between meals. Clinical studies suggest that Wegovy can reduce food cravings by influencing the brain's appetite control centres. This mechanism specifically benefits patients within the BMI range for Wegovy, as it addresses the underlying appetite dysregulation often associated with obesity and overweight conditions.
Streamlined Ordering Process For BMI-Qualified Patients
Once you've confirmed your BMI meets the criteria for Wegovy, our ordering process ensures rapid access to treatment. The initial clinical assessment takes just 3 minutes online, covering your BMI calculation, medical history, and weight management goals. Our prescribers typically complete reviews within 3 working days, though express 24-hour review is available for urgent cases. Following approval, all Wegovy doses ship via next-day delivery using temperature-controlled cold-chain logistics to maintain medication stability. This efficient process means BMI-eligible patients can begin treatment within days rather than months, avoiding the supply uncertainties that have affected Wegovy availability across the UK.
Storage And Practical Considerations For BMI-Eligible Treatment
Wegovy arrives as a pre-filled FlexTouch pen requiring refrigerated storage at 2-8°C before first use, though it remains stable at room temperature below 30°C for up to 6 weeks once removed from refrigeration. Each pen contains 4 doses for once-weekly injection, making the 0.25mg starter pen last exactly 4 weeks for BMI-qualified patients beginning treatment. The mandatory dose escalation schedule progresses every 4 weeks: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg maintenance from week 17 onwards. Patients cannot skip escalation steps, making reliable stock availability across all doses essential for treatment continuity. The 6-week room temperature stability provides excellent travel flexibility compared to alternatives requiring constant refrigeration.
BMI For Wegovy - Addressing UK Supply Chain Reliability
The BMI requirements for Wegovy create significant demand among eligible patients, making consistent supply chain management crucial for treatment success. EverydayMeds has invested in robust inventory management systems and direct manufacturer relationships to eliminate the stock shortages that have plagued other UK providers. Our real-time stock monitoring ensures that when patients meet the BMI criteria for Wegovy, every dose in their escalation pathway remains available for immediate dispatch.
This supply reliability particularly benefits patients whose BMI calculations place them at the borderline of eligibility, where treatment delays could impact their clinical window of opportunity. By maintaining complete stock coverage across all five Wegovy strengths, we ensure that BMI-qualified patients can commit to their weight management journey with confidence, knowing that supply interruptions won't derail their progress during the critical dose escalation phase.
Complete Your BMI Assessment And Order Wegovy Today
If your BMI meets the criteria for Wegovy treatment, our clinical team is ready to begin your assessment immediately with Stock Available availability across all doses. The combination of eligibility confirmation and immediate supply access makes EverydayMeds the optimal choice for BMI-qualified patients ready to start their weight management journey. Use discount code FIRST40 for new customers or DOSE25 for returning patients to access competitive pricing on all Wegovy strengths. Our GPhC-registered pharmacy #9012878 ensures full regulatory compliance whilst delivering the reliable service you need for successful long-term treatment. Visit https://everydaymeds.co.uk/collections/wegovy to complete your clinical assessment and secure your Wegovy supply today, backed by our commitment to consistent UK availability.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
